Early phase Technology Assessment of nanotechnology in oncology

Tumori

Volumn 94, Issue 2, 2008, Pages 284-290

  Retèl, Valesca P ^a   Hummel, Marjan J M ^b   Van Harten, Willem H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Early technology assessment; Nanotechnology; Oncology

Indexed keywords

PACLITAXEL; TEMOPORFIN;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DNA MICROARRAY; MEDICAL RESEARCH; MICROARRAY ANALYSIS; NANOTECHNOLOGY; ONCOLOGY; PHOTODYNAMIC THERAPY; QUALITY OF LIFE; SAFETY;

EID: 45249097578     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400222     Document Type: Conference Paper

References (22)

1. Logothetidis S: Nanotechnology in Medicine: The Medicine of Tomorrow and Nanomedicine. Hippokratia, 10(1):7-21, 2006.
2. Nie S, Xing Y, Kim GJ, Simons JW: Nanotechnology applications in cancer. Annu Rev Biomed Eng, 9: 257-288, 2007.
3. National Cancer Institute: Nanotechnology in cancer: Tools to relieve human suffering. 2008. Ref Type: Generic.
4. Verganti R: Planned Flexibility: Linking Anticipation and Reaction in Product Development Projects. Journal of Product Innovation Management, 16: 363-376, 1999.
5. Ioannidis JP: Is molecular profiling ready for use in clinical decision making? Oncologist, 12(3): 301-311, 2007.
6. Douma KF, Karsenberg K, Hummel MJ, Bueno-de-Mesquita JM, van Harten WH: Methodology of constructive technology assessment in health care. Int J Technol Assess Health Care, 23(2):162-168, 2007.
7. Paik S: Molecular assays to predict prognosis of breast cancer. Clin Adv Hematol Oncol, 5(9):681-682, 2007.
8. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. N Engl J Med, 347(25):1999-2009, 2002.
9. Bueno-de-Mesquita JM, van Harten W, Retel V, 't Veer L, van Dam F, Karsenberg K, Douma K, Van Tinteren H, Peterse J, Wesseling J, Wu T, Atsma D, Rutgers E, Brink G, Floore A, Glas A, Roumen R, Bellot F, Van Krimpen C, Rodenhuis S, van de Vijver M, Linn S: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol, 8(12):1079-1087, 2007.
10. Rogers EM: Diffusion of Innovations, 5th ed, New York, Free Press, 2003
11. Gehani RR: Technology Roadmapping for commercializing strategic innovations. Journal of Technology Management and Innovation, 2(2):31-45, 2007.
12. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871):530-536, 2002.
13. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, Saghatchian d'Assignies M, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ: Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. J Natl Cancer Inst, 98(17):1183-1192, 2006.
14. Bueno-de-Mesquita JM, Keijzer R, Linn SC, Hart AAM, Van Krimpen C, Meijers C, van 't Veer LJ, van de Vijver MJ: A new independent validation of the 70-gene signature in node-negative breast cancer. Eur J Cancer Suppl, 4(2): 131, 2006.
15. Yang TH, Chen CT, Wang CP, Lou PJ: Photodynamic therapy suppresses the migration and invasion of head and neck cancer cells in vitro. Oral Oncology, 43: 358-365, 2007.
16. Copper MP, Tan IB, Oppelaar H, Ruevekamp MC, Stewart FA: Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, 129(7): 709-711, 2003.
17. Hopper C, Kubler A, Lewis H, Tan IB, Putnam G: mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer, 111(1): 138-146, 2004.
18. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447 (7148): 1087-1093, 2007.
19. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, Schurmann P, Bogdanova N, Dork T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, Brennan P, Spurdle AB, Chenevix-Trench G, Beesley J, Mannermaa A, Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt MK, Hogervorst FB, Van't Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedren S, Hall P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, Stredrick DL, Alexander BH, Struewing JP, Pharoah PD, Easton DF: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet, 39(3): 352-358, 2007.
20. Miller MR, Dunham JP, Amores A, Cresko WA, Johnson EA: Rapid and cost-effective polymorphism identification and genotyping using restriction site associated DNA (RAD) markers. Genomic Research, 17: 240-248, 2008.
21. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ: Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol, 17 (8): 1263-1268, 2006.
22. Hummel MJ, van Rossum W, Verkerke GJ, Rakhorst G: Assessing medical technologies in development. A new paradigm of medical technology assessment. Int J Technol Assess Health Care, 16(4): 1214-1219, 2000.